Jason Pesile - 07 Mar 2023 Form 4 Insider Report for Vaxxinity, Inc.

Reporting relationship: Senior Vice President, Finance & Accounting.
Issuer ticker: N/A
Reported as of: 07 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2023, 16:00:42 UTC
Prior SEC filing: 11 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Rene Paula Molina as Attorney-in-Fact for Jason Pesile

Key filing fact

Jason Pesile filed Form 4 for Vaxxinity, Inc. on 04 Apr 2023.

Key facts

This page summarizes Jason Pesile's Form 4 filing for Vaxxinity, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2023, 16:00.

Change

Previous filing in this sequence was filed on 11 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VAXX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +32,700
Change %
Price: $0.000000
Shares after: 32,700
Date: 07 Mar 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 32,700
Exercise price: $2.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 48 equal monthly installments beginning on March 7, 2023.

SEC remarks

Senior Vice President, Finance & Accounting.